

Supplementary Tables

Supplementary Table 1. Clinical outcomes: percentage of patients (number)

	Overall	CD	UC	p
Clinical remission at week 14	32.7 (33)	30.9 (13)	33.8 (20)	0.76
Clinical remission at week 14 plus normal CRP	17.8 (18)	23.8 (10)	13.5 (8)	0.18
Clinical remission at week 22	35.7 (36)	35.7 (15)	35.6 (21)	0.99
Clinical remission at week 22 plus normal CRP	22.8 (23)	21.4 (9)	33.3 (14)	0.78
Clinical remission at week 54	40.6 (41)	52.4 (22)	45.2 (19)	0.04
Clinical remission at week 54 plus normal CRP	21.8 (22)	26.2 (11)	26.2 (11)	0.36
Mucosal healing*	39 (23)	36.8 (7)	41 (16)	0.75

*MH data are referred to patients having both baseline and follow-up endoscopy

Supplementary Table 2. Association between Median Week 6 VTL and clinical and endoscopic outcomes for UC patients (MH=mucosal healing).

	Median W6 VTL, µg/ml	IQR		Median W6 VTL, µg/ml	IQR	p
W14 remitters	31	23.8-43.7	W14 non-remitters	20.3	14.9-28.8	0.05
W22 remitters	29.4	20.3-42.6	W22 non-remitters	19.8	14.8-28.6	0.05
W54 remitters	27.9	16.4-41.2	W54 non-remitters	27.2	19.2-35.6	0.27
MH at W54	24.6	14.8-39.4	No MH at W54	27.4	15.9-38.3	0.66
MH at W54 (with baseline endoscopy)	26.6	15-36.9	No MH at W54 (with baseline endoscopy)	27.4	15.9-38.3	0.71

Supplementary Table 3. Association between Median Week 6 VTL and clinical and endoscopic outcomes for CD patients.

	Median W6 VTL, µg/ml	IQR		Median W6 VTL, µg/ml	IQR	p
W14 remitters	34.2	27.8-55.4	W14 non-remitters	29	19.1-42.3	0.16
W22 remitters	34.2	29.8-58.6	W22 non-remitters	28.7	18.2-41.3	0.08
W54 remitters	30.9	20.7-53.5	W54 non-remitters	25.4	19.7-32.4	0.4
MH at W54	50	27.4-53.6	No MH at W54	26.4	16.5-37.5	0.11
MH at W54 (with baseline endoscopy)	53	34.8-53.7	No MH at W54 (with baseline endoscopy)	24.5	16.5-32.2	0.006

Supplementary Table 4. Association between Median Week 14 VTL and clinical and endoscopic outcomes for UC patients.

	Median W14 VTL, µg/ml	IQR		Median W14 VTL, µg/ml	IQR	p
W14 remitters	22.3	18.3-25	W14 non-remitters	13.2	6.6-19	<0.0001
W22 remitters	21.7	18.9-26.8	W22 non-remitters	11	4.6-17.3	<0.0001
W54 remitters	20.4	17-27.8	W54 non-remitters	14.3	7.6-17.7	0.02
MH at W54	22.4	17.2-25	No MH at W54	12.5	7.9-17.5	0.006
MH at W54 (with baseline endoscopy)	21	17-24.6	No MH at W54 (with baseline endoscopy)	12.5	7.2-17.3	0.004

Supplementary Table 5. Association between Median Week 14 VTL and clinical and endoscopic outcomes for CD patients.

	Median W14 VTL, µg/ml	IQR		Median W14 VTL, µg/ml	IQR	p
W14 remitters	24.2 (12)	18-40.4	W14 non-remitters	19.7 (23)	12.2-37.2	0.19
W22 remitters	27.4 (13)	18.3-39	W22 non-remitters	18.4 (20)	12.6-36.7	0.17
W54 remitters	24.2 (18)	16.8-37.7	W54 non-remitters	16.3 (5)	9.2-41	0.33
MH at W54	20.9 (7)	17.3-41.4	No MH at W54	15.7 (15)	10.5-28.1	0.14
MH at W54 (with baseline endoscopy)	18.6 (5)	16-47.6	No MH at W54 (with baseline endoscopy)	11.9 (11)	8.1-18.8	0.05